| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7.0M | — | +102.6% |
| SG&A Expense | $2.3M | — | +12.7% |
| Operating Income | -$9.3M | — | -69.0% |
| Net Income | -$8.7M | — | -89.6% |
| EPS (Basic) | -$0.09 | — | -80.0% |
| EPS (Diluted) | -$0.09 | — | -80.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $54.5M | -17.4% | -39.0% |
| Current Assets | $58.5M | -14.4% | -36.9% |
| Total Assets | $58.9M | -14.1% | -36.7% |
| Current Liabilities | $6.5M | -18.5% | +243.9% |
| Total Liabilities | $6.7M | -17.0% | +235.7% |
| Stockholders' Equity | $52.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.4M | — | -127.3% |
| Capital Expenditures | $37K | — | +9.8% |
| Investing Cash Flow | -$37K | — | -9.8% |
| Financing Cash Flow | $0 | — | +100.0% |
| Free Cash Flow | -$11.5M | — | -126.5% |
| -42.6% |